Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The pharmaceutical industry is witnessing significant trends in the market for tinea corporis or ringworm, a common fungal infection, which reflect changes in attitudes towards antifungal therapies. This red and itchy rash called ringworm has also spurred greater R&D within the pharmaceutical realm. Among these is an upsurge in advanced antifungal formulations, especially topical creams, ointments and oral medication that seeks to improve efficiency of treatment and convenience for patients.
One of these trends include a growing preference for topical antifungal agents as the most preferred means of treating tinea corporis in the pharmaceutical market. Recently, use of such products increased over oral medications due to their direct application and consequent lower systemic exposure levels. Thus, advanced antifungal creams and ointments have become popular owing to their simplicity and ability to target only affected areas on the skin thereby limiting side effects related with drugs acting systemically.
Another trend in this sector is increased focus on novel broad-spectrum antifungals against variety of fungi causing tinea corporis. Fearing resistance from already available antifungals, companies are now putting resources into identifying new molecules that are more effective than previous ones. This development aligns with efforts by industry stakeholders to tackle emerging concerns surrounding mycological infections thus ensuring availability of remedies that work.
A notable feature amongst others is the increase in number of over-the-counter (OTC) anti-fungi products sold in pharmacies intended for dermatophytoses e.g., ringworms. OTC anti-fungal creams and powders have become popular due to increasing numbers of people seeking self-care options for everyday skin problems like athlete’s foot. The reason behind this trend is customer need for easily accessible answers regarding how they can treat dermatophytosis without visiting the doctor hence pushing forward consumer healthcare segment growth.
Pharmaceutical companies are keen on improving antifungal drug formulation and delivery systems for tinea corporis to improve patient compliance and treatment outcomes. Consequently, efforts are being put in place to develop improved penetration of various antifungals into skin layers such as nano-based formulations and lipid carriers. It is important that this trend further seeks to perfect the options of choice through better understanding of patients’ needs.
Also, global rise in the prevalence rates of fungal infections has significant impact on tinea corporis treatments market. Lifestyle changes, climate variations, and an increase in populations with suppressed immunity have resulted in higher occurrences of ringworms. With this end result, pharmaceutical firms are moving swiftly into the market with more antifungal drugs – making it a dynamic competition.
Consumer awareness campaigns regarding tinea corporis treatments play an essential role in determining trends seen within its treatment market. The public is constantly being educated by health care providers and pharmacists about preventive approaches towards mycological problems including early disease recognition and need for prompt medical intervention. Such developments help promote responsible self-medication practices while at the same time ensuring that individuals have information about their choices concerning dermatophytosis therapy.
Among the challenges in the pharmaceutical market for tinea corporis includes misdiagnosis and emergence of antifungal resistance. The similarity of symptoms caused by tinea corporis to that of other skin conditions raises a diagnostic challenge highlighting the importance of correctly identifying and promptly diagnosing this fungal infection. Also, overuse or misuse can render these medications ineffective due to development of resistance hence underlining why prescribers should practice judicious prescribing habits as well as educate patients.
Tinea Corporis Market Highlights:
Global Tinea Corporis Market Overview
The Tinea Corporis Market Size was valued at USD 14.24 Billion in 2023. The Global Tinea Corporis industry is projected to grow from USD 14.38 Billion in 2024 to USD 20.17 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.52% during the forecast period (2024 - 2032).
Tinea corporis is a fungal infection that is caused by tinea rubrum, trichophyton mentagrophytes and epidermophyton floccosum fungi. This fungal infection mainly occurs in humid climatic condition. It is also known as ringworm infection. Tinea corporis infection occurs mostly on arms, legs or can also occur on different parts of body. Tinea corporis is contagious infection which can spread from one person to other hence it is important not to share towel, flannels, bathmats with another person.
Tinea Corporis Market Trends
The tinea corporis market is expected to see the growth in upcoming year due to entry of new drug product in market for treatment. Many key players in market are engaged in development of new drug product for tinea corporis treatment. The prevalence of tinea infection is higher in humid climatic condition. Increasing incidences of fungal diseases and increasing prevalence of various skin disorders are some of the key factors responsible for the market growth. Various other factors such as increasing awareness regarding skin infection, new drug development, are also driving the global tinea corporis market.
However certain factors that can hamper the growth of this market in near future are lack of awareness regarding fungal disease, adverse side effect due to antifungal drugs and alternative treatment plans.
Tinea Corporis Market Segment Insights
Global tinea corporis market is segmented into drug type, diagnosis, treatment and end-users. Tinea corporis market on basis of drug types is segmented into antifungals, steroids and anti-infective combinations.
Based on diagnosis tinea corporis market is segmented into physical exam, imaging tests. Imaging test is further sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy and others.
Based on treatment tinea corporis market is segmented into antifungal shampoos, antifungal creams, drugs and others. On basis of end-user market is further segmented into hospital pharmacies, drug stores, online pharmacies, dermatology hospitals, medical research centres, academic institutes others.\
Tinea Corporis Market Drug Type Insights
- Antifungals
- Steroids
- Anti-Infective Combinations
Tinea Corporis Diagnosis Insights
- Physical Exam
- Imaging Tests
- Wood lamp (black light) examination
- Microscopy using potassium hydroxide (KOH)
- Fungal culture
- Skin biopsy
- Others
Tinea Corporis Treatment Insights
- Antifungal shampoos
- Antifungal creams
- Drugs
- Others
Tinea Corporis End-Users Insights
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
- Dermatology hospitals
- Others
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The tinea corporis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of the tinea corporis market.
The European tinea corporis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The tinea corporis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The tinea corporis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Tinea Corporis Regional Insights
Geographically, the America holds the highest market share for tinea corporis market and the reason being many market players are engaged in development of new drug product innovation, and as this infection is more prone to humid climatic condition there is an increasing prevalence of fungal infection in this region. Whereas increasing awareness of fungal disease and rising healthcare expenditure by the government are some of the factors responsible for growth of market in this region
Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of fungal infection, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region.
Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of fungal infection, changing lifestyle, increase in population, increasing healthcare expenditure by government are some of the factor responsible for market growth in this region.
Tinea Corporis Market Key players
Some of the key players in the global tinea corporis market are
- Taro Pharmaceuticals., Inc.
- Teva Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Inc
- Breckenridge Pharmaceutical, Inc.
- NorthStar Rx LLd
- Aurobindo Pharma Limited
- Camber Pharmaceuticals, Inc.
- AvKare, Inc.
- Novartis AG
- Sebela Pharmaceuticals, Inc.
- Bayer AG
- Blueberry Therapeutics Ltd
- Perrigo Company
Tinea Corporis Regional Outlook
- Americas
- North America
- US
- Canada
- South America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Republic of Korea
- Rest of Asia Pacific
- The Middle East & Africa
- Middle East
- Africa
Intended Audience
-
- Manufacturers and Suppliers
- Hospitals and Clinics
- Laboratories and Associations
- Research Institutes
- Dermatology Clinics
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
